TrialDiabetes, obesity & metabolism2026

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses.

David Z I Cherney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.